PROTACs: A Paradigm Shift in Drug Discovery – Module 3

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (3 of 5 Modules)

This activity provides an overview of emerging data in the development of proteolysis targeting chimeras (PROTACs) that harness intracellular E3-ubiquitin ligases for the treatment of hematologic malignancies.

Credit Expired

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies

Activity Faculty

Katherine Donovan, PhD

Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Featured RMEI CE Activities – Earn CE Credit(s)

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

1.25 CE Credit(s)

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

1.0 CE Credit(s)

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

0.75 CE Credit(s)

Privacy | Terms of Use